The purpose of this study was to investigate the effects of interleukin-1α (IL-1α) infusion and the ability of cyclosporin A (CYA) to alter IL-1α-induced effects on bone in vivo and in vitro and lymphoid organs in vivo. Mice were administered: IL-1α (2,4, or 6 days), CYA (6 days), or IL-1α and CYA (6 days). Hypercalcemia was induced in mice treated with IL-1α compared to controls and CYA treated mice, and decreased urinary calcium excretion was present in IL-1α and CYA groups. Osteoclastic bone resorption was increased with a resultant loss of total bone area and bone formation (as measured by mineral apposition rate) was decreased in mice infused with IL-1α. Although CYA-treatment increased bone formation as compared to IL-1α-treatment; CYA in combination with IL-1α did not alter the reduction in mineral apposition rate caused by IL-1α. IL-1α also stimulated bone resorption in vitro which was significantly inhibited by cyclosporin A. IL-1α-induced splenic granulopoiesis, peripheral blood neutrophilia, thymic atrophy, and lymphoid hyperplasia in lymph nodes. CYA-treatment resulted histologically in a severe depletion of lymphocytes in the thymus, a moderate depletion of lymphocytes in lymph nodes but no difference in the histology of the spleen compared to controls. In summary, interleukin-1α was effective in stimulating hypercalcemia and bone resorption both in vivo and in vitro but cyclosporin A was effective in inhibiting IL-1α -mediated bone resorption only in vitro. IL-1α also had marked effects on spleen, thymus, and circulating blood cells; however, most parameters were not affected by the concurrent administration of cyclosporin A.
1. Boyce BF, Aufdemorte TB, Garrett IR, Yates AJP, and Mundy GR (1989). Effects of interleukin-1 on bone turnover in normal mice. Endocrinology125:1142–1150.
2.
2. Caverzasio J, Dayer JM, Rizzoli R, and Bonjour JP (1989). Stimulatory effect of interleukin-1 beta on renal Ca reabsorption in thyroparathyroidectomized(TPTX) rats. J. Bone Miner. Res.4: S288.
3.
3. Chouaib S, Bertoglio J, Blay JY, Marchiol-Foumigault, C, and Fradelizi D (1988). Generation of lymphokine-activated killer cells: Synergy between tumor necrosis factor and interleukin-2. Proc. Natl. Acad. Sci. USA85:6875–6879.
4.
4. Clarke JT (1961). Colorimetric determination and distribution of urinary creatinine and creatine. Clin. Chem.7:371–383.
5.
5. Connolly KM, Stetcher VJ, Danis E, Pruden DJ, and LaBrie T (1988). Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin A or methotrexate. Int. J. Immunopharmacol.10:717–728.
6.
6. di Giovine FS and Duff GW (1990). Interleukin 1: The first interleukin. Immunol. Today11:45–52.
7.
7. Ghezzi P and Dinarello CA (1988). IL-1 induces IL-1. J. Immunol.140:4238–4244.
8.
8. Herrmann F, Oster W, Meuer SC, Lindemann A, and Mertelsmann RH (1988). Interleukin 1 stimulates T lymphocytes to produce granulocyte-monocyte colony-stimulating factor. J. Clin. Invest.81:1415–1418.
9.
9. Larrick JW and Kunkel SL (1988). The role of tumor necrosis factor and interleukin 1 in the immunoin-flammatory response. Pharm. Res.5:129–139.
10.
10. Lichtman AH, Chin J, Schmidt JA, and Abbas AK (1988). Role of interleukin 1 in the activation of T lymphocytes. Proc. Natl. Acad. Sci. USA85:9699–9703.
11.
11. Lindemann RA, Economou JS, and Rothermel H (1988). Production of interleukin-1 and tumor necrosis factor by human peripheral monocytes activated by periodontal bacteria and extracted lipopoly-saccharides. J. Dent. Res.67:1131–1135.
12.
12. Martin M and Resch K (1988). Interleukin-1: More than a mediator between leukocytes. Trends Pharmacol. Sci.9:171–177.
13.
13. Mason MJ and Van Epps DE (1989). In vivo neutrophil emigration in response to interleukin-1 and tumor necrosis factor-alpha. J. Leukocyte Biol.45:62–68.
14.
14. McCauley LK, Rosol TJ, Capen CC, and Horton JE (1989). A comparison of bone turnover in athymic (nude) and euthymic mice: Biochemical, histomor-phometric, bone ash and in vitro studies. Bone10:29–34.
15.
15. McCauley LK, Rosol TJ, Capen CC, Horton JE, and Shanfeld J (1989). Investigations on in vitro bone resorbing activity from athymic (nude) and euthymic mouse splenic leukocytes. Bone10:389–393.
16.
16. Movsowitz C, Epstein S, Fallon M, Ismail F, and Thomas S (1988). Cyclosporin-A in vivo produces severe osteopenia in the rat: Effect of dose and duration of administration. Endocrinology123:2571–2577.
17.
17. Movsowitz C, Epstein S, Ismail F, Fallon M, and Thomas S (1989). Cyclosporin A in the oophorectomized rat: Unexpected severe bone resorption. J. Bone Miner. Res.4:393–398.
18.
18. Mrosovsky N, Molony LA, Conn CCA, and Kluger MJ (1989). Anorexic effects of interleukin 1 in the rat. Am. J. Physiol.257: R1315–R1321.
19.
19. Newton RC, Sandlin G, Pezzella K, Huang J, and McKearn J (1989). Flow cytometric analysis of the effect of interleukin 1 administration on bone marrow populations in mice. J. Biol. Response Mod.8:155–169.
20.
20. Orcel P, Bielakoff J, Modrowski D, Miravet L, and DeVernejoul MC (1989). Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone. J. Bone Miner. Res.4:387–391.
21.
21. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, and Recker RR (1989). Bone histomorphometry: Standardization of nomenclature, symbols, and units. J. Bone Miner. Res.2:595–610.
23. Rampart M, Fiers W, de Smet W, and Herman AG (1989). Different pro-inflammatory profiles of interleukin-1 (IL1) and tumor necrosis factor (TNF) in an in vivo model of inflammation. Agents Actions26:186–188.
24.
24. Rosol TJ, Capen CC, and Horst RL (1988). Effects of infusion of human parathyroid hormone-related protein -(1–40) in nude mice: Histomorphometric and biochemical investigations. J. Bone Miner. Res.3:699–706.
25.
25. Sabatini M, Boyce B, Aufdemorte T, Bonewald L, and Mundy GR (1988). Infusions of recombinant human interleukins 1 alpha and beta cause hypercalcemia in normal mice. Proc. Natl. Acad. Sci. USA85:5235–5239.
26.
26. Sato K, Fujii Y, Kasono K, Ozawa M, Imamura H, Kanaji Y, Kurosawa H, Tsushima T, and Shizume K (1989). Parathyroid hormone-related protein and interleukin-1 alpha synergistically stimulate bone resorption in vitro and increase the serum calcium concentration in mice in vivo. Endocrinology124: 2172–2178.
27.
27. Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, and Thomas S (1989). The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology124:2179–2184.
28.
28. Shires R, Avioli LV, Bergfeld MA, Fallon MD, Slatopolsky E, and Teitelbaum SL (1980). Effects of semistarvation on skeletal homeostasis. Endocrinology107:1530–1535.
29.
29. Stashenko P, Dewhirst FE, Peros WJ, Kent RL, and Ago JM (1987). Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J. Immunol.138:1464–1468.
30.
30. Stashenko P, Obernesser MS, and Dewhirst FE (1989). Effect of immune cytokines on bone. Immunol. Invest.18:239–249.
31.
31. Stewart PJ and Stern PH (1988). Inhibition of parathyroid hormone and interleukin-1-stimulated bone resorption by cyclosporine A but not by cyclosporine H or F. Transplant. Proc.20:989–992.
32.
32. Tatakis DN, Schneeberger G, and Dziak R (1988). Recombinant interleukin-1 stimulates prostaglandin E2 production by osteoblastic cells: Synergy with parathyroid hormone. Calcif. Tissue Int.42:358–362.
33.
33. Tracey DE, Hardee MM, Richard KA, and Paslay JW (1988). Pharmacological inhibition of interleukin-1 activity on T cells by hydrocortisone, cyclosporine, prostaglandins, and cyclic nucleotides. Immunopharmacology15:47–62.
34.
34. Ulich TR, del Castillo J, Guo K, and Souza L (1989). The hematologic effects of chronic administration of the monokines tumor necrosis factor, interleukin 1, and granulocyte-colony stimulating factor on bone marrow and circulation. Am. J. Pathol.134:149–159.
2. Bolton WK, Benton FR, Maclay JG, and Sturgill BC (1976). Spontaneous glomerular sclerosis in aging Sprague-Dawley rats. Am. J. Pathol.85:277–300.
37.
3. Bovee KC (1986). Renal function and laboratory evaluation. Toxicol. Pathol.14:26–36.
38.
4. Coleman GL, Barthold SW, Osbaldiston GW, Foster SJ, and Jonas AM (1977). Pathologic changes during aging in barrier reared Fischer 344 male rats. J. Gerontology32:258–278.
39.
5. Cuppage FE, Setter K, Sullivan LP, Reitzes EJ, and Melnykovych AO (1977). Gentamicin nephrotoxicity. II. Physiological, biochemical and morphological effects of prolonged administration to rats. Virchows Arch. [B] Cell Path.24:121–128.
40.
6. Elliot WC, Houghton DC, Gilbert DN, Baines-Hunter, J, and Bennett WM (1982). Gentamicin nephrotoxicity: 1. Degree and permanence of acquired in-sensitivity. J. Lab. Clin. Med.100:501–512.
41.
7. Gilbert DN, Houghton DC, Bennett WM, Plamp CE, Reger K, and Porter GA (1979). Reversibility of gentamicin nephrotoxicity in rats: Recovery during continuous drug administration. Proc. Soc. Exp. Biol. Med.160:99–103.
42.
8. Gilbert DN, Plamp C, Starr P, Bennett WM, Houghton DC, and Porter G (1978). Comparative nephrotoxicity of gentamicin and tobramycin in rats. Antimicrob. Agents Chemother.13:34–40.
43.
9. Hottendorf GH (1982). Clinical versus experimental comparisons of aminoglycoside nephrotoxicity. In: Nephrotoxicity Ototoxicity of Drugs, JP Fillastre (ed). University of Rouen, pp. 257–268.
44.
10. Hottendorf GH, Barnett D, Gordon LL, Christensen EF, and Madissoo H (1981). Nonparallel nephrotoxicity dose response curves of aminoglycosides. Antimicrob. Agents Chemother.19:1024–1028.
45.
11. Hottendorf GH and Gordon LL (1980). Comparative low dose nephrotoxicities of gentamicin, tobramycin and amikacin. Antimicrob. Agents Chemother.18:176–181.
46.
12. Hottendorf GH and Williams PD (1986). Aminoglycoside nephrotoxicity. Toxicol. Pathol.14:66–72.
47.
13. Institute of Laboratory Animal Resources (ILAR), National Research Council (1985). Guide for the Care and Use of Laboratory Animals. NIH Publication No. 86–23.
48.
14. Kaloyanides GJ (1984). Aminoglycoside-induced functional and biochemical defects in the renal cortex. Fundam. Appl. Toxicol.4:930–943.
49.
15. Kohn OF and Barthold SW (1984). Biology and diseases of rats. In: Laboratory Animal Medicine, JG Fox, BJ Cohen, and FM Lowe (eds). Academic Press, Inc., FL, pp. 91–122.
50.
16. Kosek JC, Mazze RI, and Cousins MJ (1974). Nephrotoxicity of gentamicin. Lab. Invest.30:48–57.
51.
17. Laurent G, Maldague P, Carlier MB, and Tulkens PM (1983). Increased renal DNA synthesis in vitro after administration of low doses of gentamicin to rats. Antimicrob. Agents Chemother.24:586–593.
52.
18. Luft FC, Rankin LI, Sloan RS, and Yum MN (1978). Recovery from aminoglycoside nephrotoxicity with continued drug administration. Antimicrob. Agents Chemother.14:284–287.
53.
19. Marre R, Tarara N, Louton T, and Sack K (1980). Age-dependent nephrotoxicity and the pharmacokinetics of gentamicin in rats. Europ. J. Pediatr.133:25–29.
54.
20. McHenry MC (1984). Therapeutic aspects of aminoglycoside antibiotics. In: The Aminoglycoside Antibiotics: A Guide to Therapy, WG Barnes and GR Hodges (eds). CRC Press, Inc., FL, pp. 87–151.
55.
21. McMartin DN and Engel SG (1982). Effect of aging on gentamicin nephrotoxicity and pharmacokinetics in rats. Res. Comm. Chem. Path. Pharmacol.38:193–206.
56.
22. Ringler DH and Dabich L (1984). Hematology and clinical biochemistry. In: The Laboratory Rat, HJ Baker, JR Lindsey, and SH Weisbroth (eds). Academic Press Inc., FL, pp. 105–121.
57.
23. Tarlaff JB, Goldstein RS, Morgan DG, and Hook JB (1989). Acetaminophen and p-aminophenol nephrotoxicity in aging male Sprague-Dawley and Fischer 344 rats. Fundam. Appl. Toxicol.12:78–91.
58.
24. Whelton A and Solze K (1983). Pathophysiologic mechanisms in aminoglycoside nephrotoxicity. J. Clin. Pharmacol.23:453–460.
59.
25. Williams PD, Bennett DB, Gleason CR, and Hottendorf GH (1987). Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob. Agents Chemother.31:570–574.
60.
26. Williams PD and Hottendorf GH (1986). [3H]Gentamicin uptake in brush border and basolateral membrane vesicles from rat kidney cortex. Biochem. Pharmacol.35:2253–2256.
